Pharma BD Deal Intelligence
Biogen and Sangamo announced a global licensing collaboration to develop and commercialize ST-501 for tauopathies, ST-502 for synucleinopathies, plus an undisclosed neuromuscular target and up to nine additional neurological targets. Sangamo received $350M upfront ($125M license fee plus $225M equity) and is eligible for up to $2.37B in development, regulatory and commercial milestones plus tiered royalties. UPDATE: The collaboration closed April 3, 2020. Biogen subsequently terminated the agreement effective June 15, 2023 following a strategic pipeline review, returning all rights (including ST-501 and ST-502) to Sangamo and prioritizing its Leqembi/lecanemab launch and tau ASO BIIB080. Sangamo lost eligibility for the remaining milestones and royalties from the $2.37B pool. Novartis terminated its parallel Sangamo deal at the same time (effective June 11, 2023).